Marianne Grønlie Guren1, Bjarte Aagnes2, Mari Nygård3, Olav Dahl4, Bjørn Møller2. 1. Department of Oncology and K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway. Electronic address: marianne.gronlie.guren@ous-hf.no. 2. Department of Registration, Cancer Registry of Norway, Oslo, Norway. 3. Department of Research, Cancer Registry of Norway, Oslo, Norway. 4. Department of Oncology, Haukeland University Hospital and Institute of Clinical Science, Medical Faculty, University of Bergen, Bergen, Norway.
Abstract
BACKGROUND: Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC. MATERIALS AND METHODS: All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Norway (N = 1548), with information on age, gender, stage, county of residence, radiotherapy, and survival. RESULTS: Median age was 66 years; 71% were females. World age-standardized incidence rates increased (1987-2016) from 0.79 (95% confidence interval [CI], 0.69-0.90) to 1.10 (95% CI, 1.00-1.22) per 100,000 person-years in females and, from 0.34 (95% CI, 0.28-0.42) to 0.47 (95% CI, 0.40-0.54) in males. Estimated annual percentage change was 1.7 (95% CI, 0.9-2.6) for females and 1.3 (95% CI, -0.1 to 2.7) for males. Incidence rates increased with age; the relative risk was higher in major cities. Five-year net survival increased from 63.4% to 72.7% (1987-2016), but for age ≥ 70 years remained ∼57%. Net survival was dependant on stage, age, and gender. Five-year net survival (1997-2016) was 76.4% after curative radiotherapy, and 18.0% after palliative radiotherapy. CONCLUSION: ASCC incidence rates increased from 1987 to 2016, and survival improved for patients < 70 years. Five-year net survival was 76% after curative radiotherapy in Norway.
BACKGROUND:Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC. MATERIALS AND METHODS: All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Norway (N = 1548), with information on age, gender, stage, county of residence, radiotherapy, and survival. RESULTS: Median age was 66 years; 71% were females. World age-standardized incidence rates increased (1987-2016) from 0.79 (95% confidence interval [CI], 0.69-0.90) to 1.10 (95% CI, 1.00-1.22) per 100,000 person-years in females and, from 0.34 (95% CI, 0.28-0.42) to 0.47 (95% CI, 0.40-0.54) in males. Estimated annual percentage change was 1.7 (95% CI, 0.9-2.6) for females and 1.3 (95% CI, -0.1 to 2.7) for males. Incidence rates increased with age; the relative risk was higher in major cities. Five-year net survival increased from 63.4% to 72.7% (1987-2016), but for age ≥ 70 years remained ∼57%. Net survival was dependant on stage, age, and gender. Five-year net survival (1997-2016) was 76.4% after curative radiotherapy, and 18.0% after palliative radiotherapy. CONCLUSION: ASCC incidence rates increased from 1987 to 2016, and survival improved for patients < 70 years. Five-year net survival was 76% after curative radiotherapy in Norway.
Authors: L Cattelan; F M Ghazawi; M Le; E Savin; A Zubarev; F Lagacé; D Sasseville; K Waschke; I V Litvinov Journal: Curr Oncol Date: 2020-06-01 Impact factor: 3.677
Authors: Lily L Lai; Marta Invernizzi; Michael White; Chao Han; Huangfu Jiangtao; Helen Lu; Changhuei Yang; James Lin Journal: Sci Rep Date: 2021-02-11 Impact factor: 4.379
Authors: Anna Frennered; Jonas Scherman; Pamela Buchwald; Anders Johnsson; Hanna Sartor; Sophia Zackrisson; Elin Trägårdh; Martin P Nilsson Journal: BMC Cancer Date: 2021-04-22 Impact factor: 4.430
Authors: Anna C Lefèvre; Niels Pallisgaard; Camilla Kronborg; Karen L Wind; Søren R P Krag; Karen-Lise G Spindler Journal: Cancers (Basel) Date: 2021-05-18 Impact factor: 6.639